DSM-Firmenich AG (AMS:DSFIR)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 14.42B -47.2% |
| Revenue (ttm) | 9.03B -28.5% |
| Net Income | -1.11B |
| EPS | -4.27 |
| Shares Out | 251.53M |
| PE Ratio | 54.39 |
| Forward PE | 16.80 |
| Dividend | 2.50 (4.36%) |
| Ex-Dividend Date | May 8, 2025 |
| Volume | 43,280 |
| Average Volume | 1,100,450 |
| Open | 56.72 |
| Previous Close | 57.32 |
| Day's Range | 55.98 - 56.72 |
| 52-Week Range | 55.98 - 99.92 |
| Beta | 0.81 |
| RSI | 32.41 |
| Earnings Date | Feb 12, 2026 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and s... [Read more]
Financial Performance
Financial StatementsNews
DSM-Firmenich AG (DSMFF) Full Year 2025 Earnings Call Highlights: Navigating Growth Amid Market ...
DSM-Firmenich AG (DSMFF) Full Year 2025 Earnings Call Highlights: Navigating Growth Amid Market Challenges
Full Year 2025 DSM-Firmenich AG Earnings Call Transcript
Full Year 2025 DSM-Firmenich AG Earnings Call Transcript
Dsm-firmenich To Sell ANH Business To CVC Capital Partners For EUR 2.2 Bln; Stock Down
(RTTNews) - dsm-firmenich AG (DSFIY, DSFIR.AS), a nutrition, health, and beauty company, Monday announced its agreement to divest Animal Nutrition & Health or ANH business to private markets manager C...
Health and biotech firm says it has enjoyed resilient demand as health kick is here to stay
Dimitri de Vreeze, co-CEO of DSM, discusses his company's earnings and explains why demand has remained strong.
'A merger of equals': Firmenich CEO Ghostine on DSM deal
Firmenich CEO Gilbert Ghostine describes the company's deal with sector peer DSM as a "merger of equals."
5 Great Green Stocks Making a Direct Impact
It's the end of business as usual. To save the planet, consumers, companies and governments all over the world are stepping up their sustainability game, or at least pledging to do so.
DSM co-CEO: Inflationary pressures offset by 4% price increase in some business areas
Geraldine Matchett, co-CEO of DSM and member of CNBC's ESG Council, provides a deep dive into the company's fourth-quarter results and shares how DSM are tackling rising inflation.
Very Confident to Increase Our Outlook: DSM Co-CEO
Aug.04 -- DSM Co-CEO Dimitri de Vreeze discusses the company's earnings, emissions and sustainable foods. He speaks with Bloomberg's Anna Edwards and Mark Cudmore on "Bloomberg: European Market Open".
DSM Going Into 2021 With Positive Momentum, Says Co-CEO
Feb.16 -- Geraldine Matchett, co-chief executive officer at at Dutch Lifesciences company Koninklijke DSM NV, discusses fourth-quarter earnings, the animal nutrition business and her outlook for the b...
'Analysts failed to see the impact of foreign exchange headwinds on top line,' DSM co-CEO says
Geraldine Matchett and Dimitri de Vreeze, co-CEOs at DSM, discuss the company's third-quarter earnings and the impact of the pandemic on the business.
DSM co-CEO's say cash generation 'is a big focus' amid the coronavirus crisis
Geraldine Matchett and Dimitri de Vreeze, co-CEO's of DSM, speak to the corporation's first half of the year along with its strategy amid the uncertainty of a second wave.